+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticonvulsants Market - Global Forecast 2026-2032- Product Image
Anticonvulsants Market - Global Forecast 2026-2032- Product Image
New

Anticonvulsants Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305569
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anticonvulsants market is advancing rapidly, shaped by shifts in therapeutic practice, complex regulatory landscapes, and demands for novel commercial approaches. Senior leaders in healthcare and pharmaceuticals must actively track evolving patient needs, emerging clinical evidence, and dynamic market forces to remain competitive.

Market Snapshot: Growth Trajectory in the Anticonvulsants Market

The global anticonvulsants market grew from USD 14.23 billion in 2025 to USD 15.50 billion in 2026 and is set to reach USD 25.98 billion by 2032, representing an 8.97% CAGR. This growth is supported by increasing incidence of neurological and psychiatric conditions, demand for broader clinical indications, and greater access in developed and emerging markets. The sector's expansion underscores its pivotal role across neurology, psychiatry, and pain management, while highlighting intensified competition stemming from evolving drug classes, deployment of advanced technologies, and regional market differences.

Scope & Segmentation of the Anticonvulsants Market

This report delivers a thorough analysis of strategic, clinical, and commercial developments affecting senior decision-makers. Key areas of segmentation include:

  • Drug Classes: Benzodiazepines, carbonic anhydrase inhibitors, GABA analogues, sodium channel blockers, and SV2A modulators, each presenting diverse efficacy, safety, and interaction profiles crucial for optimizing treatment selection and aligning with prescriber strategies.
  • Clinical Indications: Addresses seizure disorders, bipolar disorder, migraine prophylaxis, and neuropathic pain—capturing the expanded use of anticonvulsants beyond traditional applications and reflecting broader patient populations targeted by these therapies.
  • Administration Routes: Encompasses oral, injectable, rectal, and transdermal dosage forms, all influencing patient adherence and healthcare delivery models across acute and long-term management.
  • Distribution Channels: Includes drug stores, hospital and retail pharmacies, as well as online pharmacies, each with implications for reimbursement, market penetration, and patient engagement strategies.
  • Regional Coverage: Features comparative analysis for Americas, EMEA (Europe, Middle East, Africa), and Asia-Pacific regions, accounting for varied regulatory climates, market access structures, and pricing environments. Regional distinctions directly affect commercialization strategies and operational planning.
  • Innovation & Technology Adoption: Examines impact of mechanism-based drug innovation, the integration of precision medicine tools, and adoption of digital technology such as remote monitoring and adherence platforms, all contributing to competitive differentiation and lifecycle management of key products.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovation is advancing with a focus on next-generation drug mechanisms and delivery systems, elevating standards for patient outcomes and compliance with regulatory benchmarks.
  • Expanded clinical utility of anticonvulsants beyond seizure control to psychiatric and chronic pain disorders drives both market opportunity and the necessity for strong evidence bases and product safety differentiation.
  • Adapting to evolving procurement and access frameworks is essential, as reimbursement policies emphasize real-world evidence and demonstration of economic value for health systems and payers.
  • Differentiation by drug class, indication, and administration route underpins product positioning, influences channel strategy, and shapes integration into clinical guidelines and formularies.
  • Developing robust supply chains and digital tools is key for continuity of active pharmaceutical ingredient sourcing, especially when responding to unexpected operational changes or regulatory disruption.
  • Regional differences in regulation and distribution models require tailored strategies to secure sustained patient access and maintain commercial momentum.

Tariff Impact on Anticonvulsant Supply Chains and Strategy

Recent changes in United States tariff regulations are prompting market participants to modify their procurement and pricing approaches. Companies are renegotiating supplier contracts, expanding their supplier base, and evaluating domestic manufacturing as alternatives. These tactical responses target mitigation of margin pressures, enhancement of supply chain resilience, and reduction of risk from external pricing volatility. Adjustments in downstream negotiations with healthcare payers and providers may increase, as cost changes ripple through the supply chain, fueling investment in process improvements and relocation of manufacturing when appropriate.

Methodology & Data Sources

This analysis employs a mixed-methods research framework, integrating structured interviews with clinicians, commercial leaders, and procurement experts, alongside comprehensive literature reviews and secondary data analysis. Insights are cross-referenced with regulatory guidance, published trials, and registry data, supplemented by sensitivity and thematic coding checks to ensure analytical consistency and integrity.

Why This Report Matters

  • Enables leadership to align investment strategies, clinical pipeline development, and operational plans with changing market demands and patient needs.
  • Delivers actionable guidance on market access, technology adoption, and regulatory adaptation, supporting improved competitive positioning and commercialization success.
  • Informs robust decision-making through a deep-dive review of market segments, regional markets, and supply chain dynamics, leveraging diverse and rigorously validated research sources.

Conclusion

Effective navigation of therapeutic advancement, resilient operations, and evidence-driven access is crucial for stakeholders in the anticonvulsants market. Forward-looking organizations prepared to address these priorities are better positioned for sustained clinical and commercial success amid ongoing market evolution.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anticonvulsants Market, by Drug Class
8.1. Benzodiazepines
8.1.1. Clobazam
8.1.2. Clonazepam
8.1.3. Diazepam
8.2. Carbonic Anhydrase Inhibitors
8.2.1. Acetazolamide
8.2.2. Methazolamide
8.3. Gaba Analogues
8.3.1. Gabapentin
8.3.2. Pregabalin
8.3.3. Vigabatrin
8.4. Sodium Channel Blockers
8.4.1. Carbamazepine
8.4.2. Lamotrigine
8.4.3. Phenytoin
8.5. Sv2A Modulators
8.5.1. Brivaracetam
8.5.2. Levetiracetam
9. Anticonvulsants Market, by Indication
9.1. Bipolar Disorder
9.1.1. Type I
9.1.2. Type II
9.2. Epilepsy
9.2.1. Absence Seizures
9.2.2. Focal Seizures
9.2.3. Generalized Seizures
9.2.4. Myoclonic Seizures
9.2.5. Status Epilepticus
9.3. Migraine Prophylaxis
9.4. Neuropathic Pain
9.4.1. Diabetic Neuropathy
9.4.2. Postherpetic Neuralgia
10. Anticonvulsants Market, by Route Of Administration
10.1. Injectable
10.2. Oral
10.3. Rectal
10.4. Transdermal
11. Anticonvulsants Market, by Distribution Channel
11.1. Drug Stores
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Anticonvulsants Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Anticonvulsants Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Anticonvulsants Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Anticonvulsants Market
16. China Anticonvulsants Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Bausch Health Companies Inc.
17.7. Biocon Limited
17.8. Cadila Pharmaceuticals Limited
17.9. Cipla, Inc.
17.10. Dr. Reddy's Laboratories Limited
17.11. Eisai Co., Ltd.
17.12. GlaxoSmithKline PLC
17.13. Glenmark Pharmaceuticals Ltd.
17.14. Jazz Pharmaceuticals, Inc.
17.15. Johnson & Johnson Services, Inc.
17.16. Lifecare Neuro Products Limited
17.17. Lundbeck A/S
17.18. Mankind Pharma Ltd.
17.19. Merck KGaA
17.20. Novartis AG
17.21. Novo Nordisk A/S
17.22. Otsuka Pharmaceutical Co., Ltd.
17.23. Pfizer Inc.
17.24. Sanofi S.A.
17.25. Sunovion Pharmaceuticals Inc.
17.26. Takeda Pharmaceutical Company Limited
17.27. Teva Pharmaceutical Industries Ltd.
17.28. Wockhardt Limited
List of Figures
FIGURE 1. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLOBAZAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CLONAZEPAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIAZEPAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ACETAZOLAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTICONVULSANTS MARKET SIZE, BY METHAZOLAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PREGABALIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTICONVULSANTS MARKET SIZE, BY VIGABATRIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTICONVULSANTS MARKET SIZE, BY PHENYTOIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BRIVARACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTICONVULSANTS MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ABSENCE SEIZURES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FOCAL SEIZURES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GENERALIZED SEIZURES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MYOCLONIC SEIZURES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANTICONVULSANTS MARKET SIZE, BY STATUS EPILEPTICUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ANTICONVULSANTS MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ANTICONVULSANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ANTICONVULSANTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. EUROPE ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 187. EUROPE ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 189. EUROPE ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 191. EUROPE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPE ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 193. EUROPE ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 194. EUROPE ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 195. EUROPE ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. EUROPE ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 213. AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. AFRICA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 215. AFRICA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 216. AFRICA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 217. AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 218. AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 219. AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 220. AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 221. AFRICA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. AFRICA ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 237. ASEAN ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. ASEAN ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 239. ASEAN ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 240. ASEAN ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 241. ASEAN ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 242. ASEAN ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 243. ASEAN ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 244. ASEAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 245. ASEAN ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 246. ASEAN ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 247. ASEAN ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 248. ASEAN ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. ASEAN ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 250. GCC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. GCC ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 252. GCC ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 253. GCC ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 254. GCC ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 255. GCC ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 256. GCC ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 257. GCC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 258. GCC ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 259. GCC ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 260. GCC ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 261. GCC ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 262. GCC ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. BRICS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. BRICS ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 278. BRICS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 279. BRICS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 280. BRICS ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 281. BRICS ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 282. BRICS ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 283. BRICS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 284. BRICS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 285. BRICS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 286. BRICS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 287. BRICS ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 288. BRICS ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 289. G7 ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 290. G7 ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 291. G7 ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 292. G7 ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 293. G7 ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 294. G7 ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 295. G7 ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 296. G7 ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 297. G7 ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 298. G7 ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 299. G7 ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 300. G7 ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 301. G7 ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 302. NATO ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 303. NATO ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 304. NATO ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 305. NATO ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 306. NATO ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 307. NATO ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 308. NATO ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 309. NATO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 310. NATO ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 311. NATO ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 312. NATO ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 313. NATO ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 314. NATO ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 315. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 325. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 326. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 327. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 328. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 329. CHINA ANTICONVULSANTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 330. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 331. CHINA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 332. CHINA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 333. CHINA ANTICONVULSANTS MARKET SIZE, BY GABA ANALOGUES, 2018-2032 (USD MILLION)
TABLE 334. CHINA ANTICONVULSANTS MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 335. CHINA ANTICONVULSANTS MARKET SIZE, BY SV2A MODULATORS, 2018-2032 (USD MILLION)
TABLE 336. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 337. CHINA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2032 (USD MILLION)
TABLE 338. CHINA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
TABLE 339. CHINA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 340. CHINA ANTICONVULSANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 341. CHINA ANTICONVU

Companies Mentioned

The key companies profiled in this Anticonvulsants market report include:
  • Abbott Laboratories
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lundbeck A/S
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 15.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 25.98 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Anticonvulsants Market Report 2025 - Product Image

Anticonvulsants Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Dravet Syndrome- Pipeline Insight, 2025 - Product Image

Dravet Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Lennox-Gastaut Syndrome Treatment Market - Global Forecast 2026-2032 - Product Image

Lennox-Gastaut Syndrome Treatment Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Infantile Spasm Therapeutics Market - Global Strategic Business Report - Product Image

Infantile Spasm Therapeutics Market - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Grand Mal Seizure Treatment Market Report 2025 - Product Image

Grand Mal Seizure Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Anticonvulsants Market

Anticonvulsants are a class of drugs used to treat seizures and other neurological disorders. They work by reducing the abnormal electrical activity in the brain that causes seizures. Anticonvulsants are used to treat a variety of conditions, including epilepsy, bipolar disorder, and neuropathic pain. They are also used to prevent seizures in people with certain types of brain injuries. Anticonvulsants are part of the larger class of Central Nervous System (CNS) drugs, which also includes antidepressants, antipsychotics, and anxiolytics. The anticonvulsant market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, and Johnson & Johnson. Other companies include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.